In a survey of adults with moderate to severe AD participating in a patient support program for upadacitinib in the United States, 86.8% reported that their itch was "very much" or "much" improved from taking the drug, while 7.8% rated their itch as minimally improved.
Also, 27.5% reported itch improvement within one day of taking upadacitinib (Rinvoq), an oral Janus kinase inhibitor that was approved to treat moderate to severe AD in adults and children aged ≥ 12 years in January 2022.
"We have a lot of data about upadacitinib from clinical trials, but sometimes there's a concern that when you start using a medication in the real world, the effectiveness doesn't match up with the efficacy observed in clinical trials," the study's first author, Jonathan I. Silverberg, MD, PhD, professor of dermatology at George Washington University, Washington, said in an interview after the Revolutionizing Atopic Dermatitis conference, where the study was presented during a late-breaking abstract session. "We always want to confirm or reaffirm clinical trial results with real-world data." Click here to read more.